Insulin Glargine Biosimilar Insight Report, 2020 by DelveInsight

Insulin Glargine Biosimilar Insight Report, 2020 by DelveInsight

DelveInsight Business Research LLP
DelveInsight’s, “Insulin Glargine Biosimilar Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in Insulin Glargine Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Insulin Glargine: Overview

Insulin glargine, marketed under the names Lantus among others, is a long-acting insulin, used in the management of type I and type II diabetes. It is typically the recommended long acting insulin in the United Kingdom. It is used once a day as an injection just under the skin. Insulin glargine is produced by recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from endogenous human insulin by the replacement of an asparagine residue at position A21 of the A-chain with glycine and addition of two arginines to the C-terminus (positions B31 and 32) of the B-chain. The resulting protein is soluble at pH 4 and forms microprecipitates at physiological pH 7.4 allowing for the slow release of small amounts of insulin glargine, giving the drug a long duration of action and no pronounced peak concentration.

Insulin Glargine Biosimilars: Drugs Chapters

This segment of the Insulin Glargine report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Insulin Glargine Biosimilars Marketed Drugs

  • Semglee: Mylan/Biocon

Semglee contains insulin glargine. This is a modified insulin, very similar to human insulin. Semglee is used to treat diabetes mellitus in adults, adolescents and children aged 2 years and above. Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar.


  • Abasaglar: Eli Lilly

Insulin glargine biosimilar (Abasaglar) is licensed for the treatment of diabetes mellitus in adults, young people and children over 2 years. Abasaglar is a basal insulin for once daily use and is bioequivalent to insulin glargine (Lantus). Basaglar is not approved for use by anyone younger than 6 years old, and should not be used to treat type 2 diabetes in a child of any age.

Further product details are provided in the report. Request here @ Insulin Glargine Therapies 

Insulin Glargine Biosimilars Emerging Drugs

  • Insulin RinGlar: Geropharm

Insulin RinGlar is being developed by Geropharm for the treatment of Type 1 diabetes mellitus. This is the fifth insulin in the company portfolio, which will complete the Geropharm line of human recombinant insulins and analogues. RinGlar will become the first insulin glargine, which will be produced in Russia on a full cycle basis – from substance to the finished dosage form.

Further product details are provided in the report.

Insulin Glargine: Therapeutic Assessment

This segment of the report provides insights about the different Insulin Glargine biosimilars segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Insulin Glargine

There are approx. 10+ key companies which are developing the therapies for Insulin Glargine.

Request here for sample pages @ Insulin Glargine Therapies 

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Insulin Glargine R&D. The therapies under development are focused on novel approaches to treat/improve Insulin Glargine.
  • In June 2020, Mylan and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Semglee (insulin glargine injection), in vial and pre-filled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications.
  • In July 2019, there was an official signing ceremony for the partnership agreement between GEROPHARM and NatiVita (Belarus) that stipulates a transfer of the Russian insulin production technology to the Belarussian party. This partnership between the companies is a strategy and facilitates strengthening bilateral relationship between the Russian Federation and the Republic of Belarus. Implementation of the project will make it possible to adjust highly technological production of insulins in Belarus within a short-term period of time and provide the citizens with modern, effective and affordable drugs.
  • In July 2019, GEROPHARM received marketing authorization for long-action insulin analog – glargine under RinGlar invented name. The drug in two dosage forms – 3 ml cartridges and pre-filled disposable insulin pens RinAstra II – will take part in the state procurement procedure in the autumn of 2019.



1. Key Insights

2. Insulin Glargine Biosimilars: Snapshot

3. Executive Summary

4. Regulatory Outlook For Biosimilars

4.1. North America

4.1.1. US

4.1.2. Canada

4.2. Europe

4.3. Asia Pacific

4.3.1. China

4.3.2. India

4.3.3. Japan

4.3.4. South Korea

4.3.5. Australia

4.4. Rest Of The World

4.4.1. Brazil

4.4.2. Mexico

4.4.3. Argentina

4.4.4. Saudi Arabia

*More Countries would be added in the final report

5. Insulin Glargine (Reference Product: Lantus)

6. Research and Development

7. Lantus Biosimilar: Emerging Opportunities

8. Insulin Glargine: Biosimilars Assessment

9. Insulin Glargine Biosimilars Profiles: By Company

9.1.1. Mylan Semglee: Mylan PDP808: Polus BioPharm

9.1.3. Biocon

9.1.4. Wockhardt

*More Companies and products would be added in the final report

10. Insulin Glargine Biosimilars: Comparative Landscape: By Company

11. Insulin Glargine Biosimilars: Competitive Landscape

*More information would be added in the final report

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix 

15.1. Research Methodology

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States